Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
OLMA
$24.69
$
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Next Earnings
2026-02-25
Beta
1.924
Average Volume
Market Cap
Last Dividend
CIK
0001750284
ISIN
US68062P1066
CUSIP
68062P106
CEO
Sean Bohen
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
96
IPO Date
2020-11-19
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript | Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript | Seeking Alpha | 2026-02-23 12:04:57 |
| Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit | Olema Pharmaceuticals (NASDAQ: OLMA) is focused on developing endocrine therapies aimed at improving outcomes for patients with estrogen receptor (ER)-positive, HER2-negative breast cancer, CEO Sean Bohen said during a company discussion hosted by Brad Canino. Bohen described the disease area as a large unmet need, noting that breast cancer is the most common cancer diagnosis in | Defense World | 2026-02-16 01:02:57 |
| Olema Pharmaceuticals, Inc. (OLMA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript | Olema Pharmaceuticals, Inc. (OLMA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript | Seeking Alpha | 2026-02-13 16:47:46 |
| Olema Oncology to Participate in Upcoming Investor Conferences | SAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Guggenheim Securities Emerging Outlook: Biotech Summit Date and Time: February 11, 2026 at 10:00 a.m. ET Format: Fireside ChatLocation: New York, NY Citi's 2026 Virtual Oncology Leadership Summit Date and Time: February 19, 2026 at 1:00 p.m. | GlobeNewsWire | 2026-02-04 16:30:00 |
| Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 24,000 shares of the Company's common stock, effective as of February 2, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4). | GlobeNewsWire | 2026-02-03 16:30:00 |
| Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Shane Kovacs, Chief Operating and Financial Officer, is departing the Company effective January 30, 2026 to pursue new opportunities. Mr. Kovacs will continue in a consulting capacity with Olema through August 1, 2026. | GlobeNewsWire | 2026-01-30 16:01:00 |
| Campbell & CO Investment Adviser LLC Buys New Shares in Olema Pharmaceuticals, Inc. $OLMA | Campbell and CO Investment Adviser LLC bought a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 29,048 shares of the company's stock, valued at approximately $284,000. Other institutional investors also | Defense World | 2026-01-24 03:14:52 |
| Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 3,489 Shares | Olema Pharmaceuticals, Inc. (NASDAQ: OLMA - Get Free Report) Director Cyrus Harmon sold 3,489 shares of the business's stock in a transaction that occurred on Wednesday, January 14th. The stock was sold at an average price of $29.12, for a total value of $101,599.68. Following the sale, the director owned 737,770 shares of the company's stock, | Defense World | 2026-01-20 06:21:12 |
| Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha | 2026-01-15 12:05:57 |
| Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of “Moderate Buy” from Brokerages | Shares of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the ten analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy | Defense World | 2026-01-12 01:28:56 |
| Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 8 new employees to purchase an aggregate of 223,500 shares of the Company's common stock, effective as of January 2, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4). | GlobeNewsWire | 2026-01-05 16:30:00 |
| Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference | SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D. | GlobeNewsWire | 2026-01-05 07:00:00 |
| Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Director Sells $82,194.93 in Stock | Olema Pharmaceuticals, Inc. (NASDAQ: OLMA - Get Free Report) Director Cyrus Harmon sold 2,881 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $28.53, for a total transaction of $82,194.93. Following the sale, the director owned 741,259 shares of the company's stock, valued at approximately | Defense World | 2026-01-02 04:52:52 |
| David Myles Sells 51,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock | Olema Pharmaceuticals, Inc. (NASDAQ: OLMA - Get Free Report) insider David Myles sold 51,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $30.46, for a total transaction of $1,553,460.00. Following the completion of the sale, the insider owned 551,881 shares of | Defense World | 2025-12-25 05:16:55 |
| Naseem Zojwalla Sells 70,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock | Olema Pharmaceuticals, Inc. (NASDAQ: OLMA - Get Free Report) insider Naseem Zojwalla sold 70,000 shares of the company's stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $28.20, for a total transaction of $1,974,000.00. Following the completion of the transaction, the insider owned 103,997 shares in | Defense World | 2025-12-25 05:16:55 |
| Ian Clark Sells 264,800 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock | Olema Pharmaceuticals, Inc. (NASDAQ: OLMA - Get Free Report) Director Ian Clark sold 264,800 shares of the company's stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $29.73, for a total value of $7,872,504.00. The transaction was disclosed in a filing with the Securities and Exchange | Defense World | 2025-12-25 04:29:07 |
| Naseem Zojwalla Sells 99,509 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock | Olema Pharmaceuticals, Inc. (NASDAQ: OLMA - Get Free Report) insider Naseem Zojwalla sold 99,509 shares of the company's stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $27.66, for a total transaction of $2,752,418.94. Following the completion of the sale, the insider directly owned 4,488 shares in the | Defense World | 2025-12-25 04:29:05 |
| Naseem Zojwalla Sells 100,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock | Olema Pharmaceuticals, Inc. (NASDAQ: OLMA - Get Free Report) insider Naseem Zojwalla sold 100,000 shares of the company's stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $28.04, for a total transaction of $2,804,000.00. Following the completion of the sale, the insider directly owned 53,997 shares | Defense World | 2025-12-25 04:28:59 |
| Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal | Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic breast cancer in pivotal phase 3 trials. Company's palazestrant + KISQALI combination achieved a promising 15.5-month mPFS in heavily pretreated patients, addressing endocrine resistance in both ESR1-mutant and wild-type tumors. Key catalysts include OPERA-01 monotherapy data expected in 2H 2026 and OPERA-02 topline results in 2028, with potential NDA filing in 2027 for monotherapy if successful. | Seeking Alpha | 2025-12-24 09:00:00 |
| Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Recommendation of “Moderate Buy” by Brokerages | Olema Pharmaceuticals, Inc. (NASDAQ: OLMA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to | Defense World | 2025-12-18 01:42:52 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-17 | 2026-02-17 | View Filing |
| 3 | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 8-K | 2026-01-30 | 2026-01-30 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-16 | 2026-01-16 | View Filing |
| 4 | 2026-01-15 | 2026-01-15 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-29 | 2025-12-29 | View Filing |
| 4 | 2025-12-23 | 2025-12-23 | View Filing |
| 4 | 2025-12-23 | 2025-12-23 | View Filing |
| 4 | 2025-12-23 | 2025-12-23 | View Filing |
| S-3ASR | 2025-12-11 | 2025-12-11 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-01 | 2025-12-01 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| 8-K | 2025-11-19 | 2025-11-19 | View Filing |
| 424B5 | 2025-11-19 | 2025-11-19 | View Filing |
| S-3MEF | 2025-11-18 | 2025-11-18 | View Filing |
| 424B5 | 2025-11-18 | 2025-11-18 | View Filing |
| 8-K | 2025-11-18 | 2025-11-18 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-10-20 | 2025-10-20 | View Filing |
| 4 | 2025-09-18 | 2025-09-18 | View Filing |
| 8-K | 2025-09-02 | 2025-09-02 | View Filing |
| 10-Q | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 8-K | 2025-06-13 | 2025-06-13 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13D/A | 2025-05-13 | 2025-05-13 | View Filing |
| 4/A | 2025-05-13 | 2025-05-13 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| ARS | 2025-04-28 | 2025-04-28 | View Filing |
| DEFA14A | 2025-04-28 | 2025-04-28 | View Filing |
| DEF 14A | 2025-04-28 | 2025-04-28 | View Filing |
| SC 13G | 2025-04-15 | 2025-04-15 | View Filing |
| S-8 | 2025-03-18 | 2025-03-18 | View Filing |
| 10-K | 2025-03-18 | 2025-03-18 | View Filing |
| 8-K | 2025-03-18 | 2025-03-18 | View Filing |
| 8-K | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-03 | 2025-03-03 | View Filing |
| 4 | 2025-03-03 | 2025-03-03 | View Filing |
| 4 | 2025-03-03 | 2025-03-03 | View Filing |
| 4 | 2025-03-03 | 2025-03-03 | View Filing |
| 4 | 2025-03-03 | 2025-03-03 | View Filing |
| 3 | 2025-02-28 | 2025-02-28 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| EFFECT | 2025-01-16 | 2025-01-16 | View Filing |
| EFFECT | 2025-01-16 | 2025-01-16 | View Filing |
| 424B5 | 2025-01-15 | 2025-01-15 | View Filing |
| 424B3 | 2025-01-15 | 2025-01-15 | View Filing |
| 4 | 2025-01-14 | 2025-01-14 | View Filing |
| 4 | 2025-01-13 | 2025-01-13 | View Filing |
| 3 | 2025-01-13 | 2025-01-13 | View Filing |
| SC 13G/A | 2025-01-13 | 2025-01-13 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| 8-K | 2025-01-10 | 2025-01-10 | View Filing |
| S-3 | 2025-01-06 | 2025-01-06 | View Filing |
| S-3 | 2025-01-03 | 2025-01-03 | View Filing |
| 4/A | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-11 | 2024-12-11 | View Filing |
| 4 | 2024-12-11 | 2024-12-11 | View Filing |
| 4 | 2024-12-11 | 2024-12-11 | View Filing |
| 4 | 2024-12-11 | 2024-12-11 | View Filing |
| 4 | 2024-12-11 | 2024-12-11 | View Filing |
| D | 2024-12-12 | 2024-12-11 | View Filing |
| SC 13G | 2024-12-11 | 2024-12-11 | View Filing |
| 8-K | 2024-12-10 | 2024-12-10 | View Filing |
| 4 | 2024-12-04 | 2024-12-04 | View Filing |
| SC 13D/A | 2024-12-04 | 2024-12-04 | View Filing |
| 8-K | 2024-12-02 | 2024-12-02 | View Filing |
| 4/A | 2024-11-26 | 2024-11-26 | View Filing |
| 4 | 2024-11-18 | 2024-11-18 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| RSI Overbought Strategy | 13.78% | 0.99 | 6 | 0.59 | 2.07 | 27.89 |
| Williams PercentR Strategy | 13.62% | 1.35 | 21 | 0.51 | 0.28 | 27.74 |
| Quantum Inspired Strategy | 12.14% | 1 | 24 | 0.5 | 0.57 | 34.67 |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | xxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxx | xxxxxx% | x | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxx | xxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | x | x | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |